Top 10 Pramipexole (Mirapex) Generic Manufacturers in Mexico
The global market for pramipexole, a dopamine agonist used primarily in the treatment of Parkinson’s disease and restless legs syndrome, is witnessing significant growth. In 2022, the global pramipexole market was valued at approximately $1.5 billion, with a projected compound annual growth rate (CAGR) of around 5.5% through 2030. Mexico has emerged as a key player in the generic pharmaceutical sector, bolstered by its strategic location and increasing investment in healthcare. The country is expected to see a surge in the production of generics, including pramipexole, driven by rising demand and favorable regulations.
1. Laboratorios PiSA
Laboratorios PiSA is one of Mexico’s leading pharmaceutical manufacturers, specializing in generic drugs, including pramipexole. The company has a market share of approximately 15% in the generic segment and produces around 500 million units annually across various therapeutic categories. Their commitment to quality and affordability positions them as a significant player in the pramipexole market.
2. Sanofi Mexico
Sanofi, a global healthcare leader, operates a robust manufacturing facility in Mexico, focusing on generics and specialty medications. While primarily known for branded products, their generic division, including pramipexole, accounts for a substantial portion of the generic market. The company reported a production volume of over 600 million units in 2022, contributing to its 10% market share in the country.
3. Grupo Farmacéutico Asofarma
Asofarma is a prominent player in the Mexican pharmaceutical landscape, known for producing high-quality generics. The company is recognized for its commitment to innovation and compliance with international standards. Asofarma’s pramipexole generics have captured about 8% of the market, with an estimated production volume of 300 million units annually.
4. Genomma Lab
Genomma Lab is a well-established name in the Mexican pharmaceutical market, with a diverse portfolio that includes generics. The company has a market share of around 7% and produces approximately 400 million units per year. Their pramipexole generics have gained popularity due to effective marketing strategies and competitive pricing.
5. Laboratorios Liconsa
Laboratorios Liconsa specializes in the development and manufacturing of generic pharmaceuticals, including pramipexole. With a production capacity of approximately 200 million units annually, Liconsa holds about 6% of the market share in the generic sector. Their focus on quality assurance and affordability enhances their standing in the industry.
6. Meda Pharmaceuticals (Mylan)
Meda Pharmaceuticals, now part of Mylan, has a significant presence in the Mexican generics market. The company produces pramipexole as part of its extensive generic portfolio, contributing to a market share of approximately 5%. Their production volume reaches around 250 million units, indicating robust demand for their products.
7. Fresenius Kabi
Fresenius Kabi is a global healthcare company that manufactures a wide range of pharmaceuticals, including pramipexole, in Mexico. The company has a market share of about 4% in the generic sector and produces around 150 million units annually. Their focus on biosimilars and generics ensures a steady supply of critical medications.
8. Sandoz (a Novartis division)
Sandoz is a leading manufacturer of generic pharmaceuticals worldwide and operates in Mexico with a diverse product range, including pramipexole. With a market share of approximately 4%, Sandoz produces around 180 million units annually, benefiting from Novartis’s extensive research and development capabilities.
9. Laboratorios Farmacéuticos de México (LFM)
LFM is a notable player in the Mexican generic drug market, specializing in high-quality medications, including pramipexole. The company holds a market share of about 3% and has a production capacity of approximately 100 million units annually. Their competitive pricing and focus on customer needs contribute to their steady growth in the market.
10. Eurofarma
Eurofarma is a Brazilian pharmaceutical company with a significant presence in Mexico. The company offers a wide range of generics, including pramipexole, and has a market share of around 3%. With an annual production volume of approximately 120 million units, Eurofarma is committed to expanding its footprint in the Mexican market.
Insights and Future Trends
The Mexican pharmaceutical market is poised for continued growth, particularly in the generic segment, which is projected to reach a market size of $5 billion by 2025. This growth is attributed to increasing healthcare demands, rising prevalence of chronic diseases, and favorable governmental policies promoting generics. With a CAGR of 6% expected in the next five years, manufacturers of pramipexole and other generics are likely to innovate and expand their production capabilities. Additionally, the Mexican government’s efforts to enhance healthcare access and affordability will further stimulate demand, making it a lucrative market for pharmaceutical manufacturers looking to invest in generics.
Related Analysis: View Previous Industry Report
